Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of the first 5 years of dedicated FDG PET/CT for Cardiac Inflammation.

Irish medical journal·2025
Same author

Incidence of cerebrovascular accident following head and neck free tissue transfer surgery.

International journal of oral and maxillofacial surgery·2022
Same author

Letter to the Editor: Dietitian Perspectives: Are We Ready for Nutrition Risk Screening in Community and Primary Care?

The journal of nutrition, health & aging·2022
Same author

Letter to the Editor: Challenges Providing Nutrition Care during the COVID-19 Pandemic: Canadian Dietitian Perspectives.

The journal of nutrition, health & aging·2021
Same author

Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data.

Diabetic medicine : a journal of the British Diabetic Association·2017
Same author

Prophylactic gastrostomy for head & neck cancer: 5 year experience from a tertiary referral centre.

Clinical nutrition ESPEN·2017

Related Experiment Video

Updated: Jul 14, 2026

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

Medical therapy for intermittent claudication.

T E Rowlands1, R Donnelly

  • 1Department of Surgery, Derby Hospitals NHS Foundation Trust, University of Nottingham, UK.

European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
|May 29, 2007
PubMed
Summary

Cilostazol, a phosphodiesterase III inhibitor, effectively improves walking distance and quality of life for intermittent claudication patients. This review synthesizes evidence from trials of cilostazol and explores therapeutic angiogenesis for peripheral arterial disease.

More Related Videos

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Related Experiment Videos

Last Updated: Jul 14, 2026

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
09:56

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia

Published on: March 6, 2026

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
14:52

Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication

Published on: December 11, 2013

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
10:50

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Area of Science:

  • Vascular Medicine
  • Pharmacology

Background:

  • Intermittent claudication (IC) management involves lifestyle changes, surgery, and medical therapy.
  • Medical therapy aims to improve symptoms, stabilize vascular disease, and enhance lower limb outcomes.

Observation:

  • Randomized controlled trials demonstrate cilostazol (100mg twice daily) improves pain-free and maximum walking distances.
  • Cilostazol enhances quality of life in IC patients without tissue necrosis or rest pain.

Findings:

  • This review summarizes 8 pivotal trials of cilostazol involving over 2000 IC patients over 6 months.
  • Evidence for other intermittent claudication symptom relief modalities is less robust.
  • Therapeutic angiogenesis is an area of interest for promoting new vessel formation in peripheral arterial disease.

Implications:

  • Cilostazol is an effective medical therapy for intermittent claudication, improving functional capacity and quality of life.
  • Further research into therapeutic angiogenesis holds promise for enhancing lower limb collateralization in peripheral arterial disease.